Chiusura precedente | 2,1450 |
Aperto | 2,1900 |
Denaro | 0,0000 x 1000 |
Lettera | 0,0000 x 3100 |
Min-Max giorno | 2,0750 - 2,2400 |
Intervallo di 52 settimane | 1,4500 - 6,9800 |
Volume | |
Media Volume | 833.533 |
Capitalizzazione | 152,23M |
Beta (5 anni mensile) | 1,87 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -1,2100 |
Prossima data utili | 21 feb 2024 - 26 feb 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 5,83 |
Stephen Dilly Headshot Stephen Dilly, MBBS, PhD, President & CEO of Codexis, Inc. REDWOOD CITY, Calif., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced President and Chief Executive Officer Stephen Dilly, MBBS, PhD, has been named the winner of the prestigious 2023 Bloom Burton Award. Dr. Dilly was recognized for his leadership of Vancouver-headquartered Sierra Oncology where he led the company through Phase 3 clinical develo
Stephen Dilly Headshot Stephen Dilly, MBBS, PhD, President & CEO of Codexis, Inc. REDWOOD CITY, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Codexis, has been named a finalist for the prestigious 2023 Bloom Burton Award. Bestowed annually and nominated by the public at large, the Bloom Burton Award honors an individual who made the greatest contribu
REDWOOD CITY, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the Cantor Global Healthcare Conference, being held September 26-28, 2023, in New York, New York. Management will participate in a fireside chat on Tuesday, September 26, 2023, at 9:20 am ET. A live webcast of the event will be available in the Investor Relations section of the Company’s website, http://ir.codexis.com. A replay will